In metastatic melanomas, it has been reported in the past that the selective activation of Akt3, but not Akt1/2, increases the survival rate of tumorigenic cells and tumor development in 40–60% of non-familial melanomas [45]. This evidence concerns the gene AKT1 and metastatic melanoma.